[ 68 Ga]Ga-PG2-2FAPI: A DPro-Gly-Modified Dimeric FAPI Probe with Enhanced Tumor Uptake and Retention
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01824 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Qing Ruan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Beam Technology of the Ministry of Education, School of Physics and Astronomy, Beijing Normal University, Beijing 100875, P.R. Chin…. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Radiopharmaceuticals, Membrane Proteins. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
In this study, a novel fibroblast activation protein (FAP) targeting ligand based on the bivalent DPro-Gly structure, DOTA-PG2-2FAPI, was designed and synthesized. Molecular docking analysis revealed that compared with monomeric FAPI-46, DOTA-PG2-2FAPI had a higher binding score (-15.00 vs -11.36), with an in vitro IC50 value of 6.65 nM, indicating a significantly increased binding affinity toward FAP. The 68Ga-labeled complex ([68Ga]Ga-PG2-2FAPI) demonstrated radiochemical purity exceeding 95% with good stability and high hydrophilicity (LogD7.4 = -3.29 ± 0.06). In HT-1080-FAP cells, the cellular uptake of [68Ga]Ga-PG2-2FAPI reached 10.98 ± 0.10% ID, which decreased by 92% upon FAP inhibition. In vivo studies using tumor-bearing mice revealed that the tumor uptake of [68Ga]Ga-PG2-2FAPI was 17.60 ± 1.33% ID/g in HT-1080-FAP tumors and 32.71 ± 0.98% ID/g in U87MG tumors, which was significantly greater than that in nontargeted tissues. Positron emission tomography (PET) imaging revealed rapid tumor accumulation and sustained retention, with high-specificity imaging across all four tumor models (HT-1080-FAP, U87MG, HT-29, and PANC-1). On the basis of these characteristics, this probe holds promise as a broad-spectrum tumor imaging agent with significant clinical application value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Beam Technology of the Ministry of Education, School of Physics and Astronomy, Beijing Normal University, Beijing 100875, P.R. China.
- Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Norm…
- Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, P.R. China.
ORCID-Profile: Qing Ruan, Yuhao Jiang, Zuojie Li, Junbo Zhang
Förderung
- Natural Science Foundation of Beijing Municipality
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Beijing Nova Program
Zitieren
APA
Ruan, Q., Jiang, Y., Li, Z., Duan, X., Diao, L., Ding, D., Han, P., Yin, G., Jiang, J., & Zhang, J. (2026). [ 68 Ga]Ga-PG2-2FAPI: A DPro-Gly-Modified Dimeric FAPI Probe with Enhanced Tumor Uptake and Retention. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01824
Vancouver
Ruan Q, Jiang Y, Li Z, Duan X, Diao L, Ding D, et al. [ 68 Ga]Ga-PG2-2FAPI: A DPro-Gly-Modified Dimeric FAPI Probe with Enhanced Tumor Uptake and Retention. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01824
BibTeX
@article{Ruan2026,
author = {Ruan, Qing and Jiang, Yuhao and Li, Zuojie and Duan, Xiaojiang and Diao, Lina and Ding, Dajie and Han, Peiwen and Yin, Guangxing and Jiang, Jianyong and Zhang, Junbo},
title = {[ 68 Ga]Ga-PG2-2FAPI: A DPro-Gly-Modified Dimeric FAPI Probe with Enhanced Tumor Uptake and Retention},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01824}
}
EUVIMED